Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy

Open access
Teepen, Jop C., van Leeuwen, Flora E., Tissing, Wim J., van Dulmen-den Broeder, Eline, van den Heuvel-Eibrink, Marry M., van der Pal, Helena J., Loonen, Jacqueline J., Bresters, Dorine, Versluys, Birgitta, Neggers, Sebastian J.C.M.M., Jaspers, Monique W.M., Hauptmann, Michael, van der Heiden-van der Loo, Margriet, Visser, Otto, Kremer, Leontien C.M., Ronckers, Cécile M., the DCOG LATER Study Group·2017·Journal of Clinical Oncology

Abstract

Purpose: Childhood cancer survivors (CCSs) are at increased risk for subsequent malignant neoplasms (SMNs). We evaluated the long-term risk of SMNs in a well-characterized cohort of 5-year CCSs, with a particular focus on individual chemotherapeutic agents and solid cancer risk. Methods: The Dutch Childhood Cancer Oncology Group–Long-Term Effects After Childhood Cancer cohort includes 6,165 5-year CCSs diagnosed between 1963 and 2001 in the Netherlands. SMNs were identified by linkages with the Netherlands Cancer Registry, the Dutch Pathology Registry, and medical chart review. We calculated standardized incidence ratios, excess absolute risks, and cumulative incidences. Multivariable Cox proportional hazard regression analyses were used to evaluate treatment-associated risks for breast cancer, sarcoma, and all solid cancers. Results: After a median follow-up of 20.7 years (range, 5.0 to 49.8 years) since first diagnosis, 291 SMNs were ascertained in 261 CCSs (standardized incidence ratio, 5.2; 95% CI, 4.6 to 5.8; excess absolute risk, 20.3/10,000 person-years). Cumulative SMN incidence at 25 years after first diagnosis was 3.9% (95% CI, 3.4% to 4.6%) and did not change noticeably among CCSs treated in the 1990s compared with those treated earlier. We found dose-dependent doxorubicin-related increased risks of all solid cancers ( P trend < .001) and breast cancer ( P trend < .001). The doxorubicin-breast cancer dose response was stronger in survivors of Li-Fraumeni syndrome–associated childhood cancers (leukemia, CNS, and non-Ewing sarcoma) versus survivors of other cancers ( P difference = .008). In addition, cyclophosphamide was found to increase sarcoma risk in a dose-dependent manner ( P trend = .01). Conclusion: The results strongly suggest that doxorubicin exposure in CCSs increases the risk of subsequent solid cancers and breast cancer, whereas cyclophosphamide exposure increases the risk of subsequent sarcomas. These results may inform future childhood cancer treatment protocols and SMN surveillance guidelines for CCSs.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2016.71.6902

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 222

Metadata

Authors
Teepen, J. C., van Leeuwen, F. E., Tissing, W. J., van Dulmen-den Broeder, E., van den Heuvel-Eibrink, M. M., van der Pal, H. J., Loonen, J. J., Bresters, D., Versluys, B., Neggers, S. J. C. M. M., Jaspers, M. W. M., Hauptmann, M., van der Heiden-van der Loo, M., Visser, O., Kremer, L. C. M., Ronckers, C. M., & the DCOG LATER Study Group
Venue
Journal of Clinical Oncology
Published
2017-07-10
Volume
35
Issue
20
Pages
2288-2298
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2618647272
Cited by
222
References
1
FWCI
15.21
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2016.71.6902
The paper
Teepen, J. C., van Leeuwen, F. E., Tissing, W. J., van Dulmen-den Broeder, E., van den Heuvel-Eibrink, M. M., van der Pal, H. J., Loonen, J. J., Bresters, D., Versluys, B., Neggers, S. J. C. M. M., Jaspers, M. W. M., Hauptmann, M., van der Heiden-van der Loo, M., Visser, O., Kremer, L. C. M., Ronckers, C. M., & the DCOG LATER Study Group. (2017). Long-Term Risk of Subsequent Malignant Neoplasms After Treatment of Childhood Cancer in the DCOG LATER Study Cohort: Role of Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.71.6902

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.